Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10040086 | 0.73 | KDM4E (0.36) | HTTMEN1HPGDKMT2A | |
| SCHEMBL13287986 | 0.65 | SMN1; SMN2 (0.35) | HTTHPGDKMT2A | |
| SCHEMBL10070241 | 0.65 | SMN1; SMN2 (0.35) | HTTHPGDKMT2A | |
| SCHEMBL26241847 | 0.61 | SMN1; SMN2 (0.36) | KMT2A | |
| SCHEMBL14151520 | 0.59 | KDM4E (0.33) | MEN1KMT2A | |
| SCHEMBL25151812 | 0.58 | — | — | |
| SCHEMBL14151742 | 0.58 | SORD (0.33) | — | |
| SCHEMBL25852448 | 0.55 | KDM4E (0.30) | — | |
| SCHEMBL10423801 | 0.54 | ALDH1A1 (0.34) | MEN1HPGDKMT2A | |
| SCHEMBL18773508 | 0.54 | SCN9A (0.40) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404732-B2 | Methods of treating ulcerative colitis | LEXICON PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20130005775-A1 | METHODS OF TREATING ULCERATIVE COLITIS | LEXICON PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8093267-B2 | Methods of treating rheumatoid arthritis | LEXICON PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| CN-102196808-A | S1P lyase inhibitors for the treatment of cerebral malaria | LEXICON PHARMACEUTICALS INC | 2011-09-21 | — | — | CN | disclosed |
| CN-101878030-A | Compositions and methods for treating immunological and inflammatory diseases and disorders | LEXICON PHARMACEUTICALS INC | 2010-11-03 | — | — | CN | disclosed |
| US-7825150-B2 | Compositions and methods for treating immunological and inflammatory diseases and disorders | LEXICON PHARMACEUTICALS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100113530-A1 | S1P LYASE INHIBITORS FOR THE TREATMENT OF CEREBRAL MALARIA | LEXICON PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
| US-20100076030-A1 | METHODS OF TREATING RHEUMATOID ARTHRITIS | LEXICON PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| CN-101395141-A | Imidazolyl compounds, compositions comprising the same, and methods of use thereof | LEXICON PHARMACEUTICALS INC (US) | 2009-03-25 | — | — | CN | disclosed |
| US-20090068180-A1 | COMPOSITIONS AND METHODS FOR TREATING IMMUNOLOGICAL AND INFLAMMATORY DISEASES AND DISORDERS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113530-A1 | S1P LYASE INHIBITORS FOR THE TREATMENT OF CEREBRAL MALARIA | S1PR1, S1PR2, SPHK1 | HTT 4672/4885MEN1 2252/4885HPGD 948/4885 |
| US-20090068180-A1 | COMPOSITIONS AND METHODS FOR TREATING IMMUNOLOGICAL AND INFLAMMATORY DISEASES AND DISORDERS | ASAH2, SGMS1, SMPD1 | HTT 4304/4885MEN1 2262/4885HPGD 666/4885 |
| US-20100076030-A1 | METHODS OF TREATING RHEUMATOID ARTHRITIS | SSB, NFKBIA, MPO | HTT 3411/4885MEN1 4596/4885HPGD 243/4885 |
| US-20130005775-A1 | METHODS OF TREATING ULCERATIVE COLITIS | SI, S1PR2, SPHK2 | HTT 4882/4885MEN1 4464/4885HPGD 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.